Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies. The SESAME-study

Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies. The SESAME-study

Bibliographic Details
Main Authors:	Y.J.L. Bodar, B.P.F. Koene, D. Meijer, P.J. Van Leeuwen, J.A. Nieuwenhuijzen, R.J.A. Van Moorselaar, N.H. Hendrikse, D.E. Oprea-Lager, A.N. Vis
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320360699

Similar Items

Detection of intraprostatic tumor localisation with 18-Fluorine Prostate-Specific Membrane Antigen (PSMA) PET/CT compared to radical prostatectomy specimens: Is PSMA-targeted biopsy feasible? the DeTeCT trial
by: Y.J.L. Bodar, et al.
Published: (2020-07-01)

Standardized uptake values are adequate measures of [18F]DCFPyL PSMA PET/CT uptake in patients with low prostate cancer disease burden
by: Y.J.L. Bodar, et al.
Published: (2020-11-01)

Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: Tumor localizations using PSMA PET/CT imaging
by: D. Meijer, et al.
Published: (2020-11-01)

Prospective evaluation of pelvic lymph node staging with 18fluorine prostate-specific membrane antigen PET/CT prior to extended lymph node dissection in primary prostate cancer – the SALT trial
by: B.H.E. Jansen, et al.
Published: (2020-07-01)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
by: Wietske I. Luining, et al.
Published: (2022-02-01)

Determining the predictive value of a pre-operative negative PSMA PET/CT in candidates for radical prostatectomy and extended pelvic lymph node dissection
by: D. Meijer, et al.
Published: (2020-11-01)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01)

External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
by: Henk B. Luiting, et al.
Published: (2021-06-01)

The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer
by: Wietske I. Luining, et al.
Published: (2024-01-01)

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels
by: Dennie Meijer, et al.
Published: (2019-07-01)

Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
by: Dennie Meijer, et al.
Published: (2020-01-01)

Estetrol improves quality of life in advanced castration-sensitive prostate cancer: A randomized clinical trial
by: R.J.A. Van Moorselaar, et al.
Published: (2022-08-01)

The effect on quality of life of androgen deprivation therapy (ADT) combined with local external prostate radiotherapy in patients with primary metastatic prostate cancer, results from the HORRAD trial
by: L.M.S. Boevé, et al.
Published: (2020-07-01)

Higher Preoperative Maximum Standardised Uptake Values (SUV<sub>max</sub>) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]DCFPyL Positron Emission Tomography/Computed Tomography
by: Katelijne C. C. de Bie, et al.
Published: (2023-07-01)

Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers
by: Wietske I. Luining, et al.
Published: (2021-01-01)

Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer.
by: Wietske I Luining, et al.
Published: (2023-01-01)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
by: Bastiaan M. Privé, et al.
Published: (2021-11-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
by: Bastiaan M. Privé, et al.
Published: (2020-09-01)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
by: Magdalena Staniszewska, et al.
Published: (2021-07-01)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
by: Lorenzo Cereser, et al.
Published: (2023-08-01)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
by: Kristin A. Plichta, et al.
Published: (2021-11-01)

The Impact of Omitting Contralateral Systematic Biopsy on the Surgical Planning of Patients with a Unilateral Suspicious Lesion on Magnetic Resonance Imaging Undergoing Robot-assisted Radical Prostatectomy for Prostate Cancer
by: Daniël L. van den Kroonenberg, et al.
Published: (2024-05-01)

Skeletal F-PSMA-1007 uptake in prostate cancer patients
by: Jorinde Janssen, et al.
Published: (2023-06-01)

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer
by: Niranjan Meher, et al.
Published: (2023-02-01)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
by: Mark Topoozian, et al.
Published: (2023-09-01)

The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer
by: Adam M. Kase, et al.
Published: (2022-03-01)

The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory
by: Sathianathen, N, et al.
Published: (2017)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
by: Hui Wang, et al.
Published: (2023-11-01)

PSMA-targeted therapy for non-prostate cancers
by: Jarey H. Wang, et al.
Published: (2023-08-01)

The prostate cancer urinary exosome protein biomarker landscape
by: I. Bijnsdorp, et al.
Published: (2020-07-01)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
by: Alexander D. Combes, et al.
Published: (2022-10-01)

Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
by: Thomas J. W. Klein Nulent, et al.
Published: (2020-06-01)

Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options
by: Lotte G. Zuur, et al.
Published: (2023-05-01)

Identification of the prostate cancer exosome surface proteome and its application to detect prostate cancer in urine
by: A. Erozenci, et al.
Published: (2020-07-01)

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer
by: Hu Siqi, Zhang Yong
Published: (2022-01-01)

A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications
by: K.S. Ajish Kumar, et al.
Published: (2022-12-01)

PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
by: Amina Banda, et al.
Published: (2022-12-01)

PSMA-Directed Radioligand Therapy for Metastatic Prostate Cancer
by: Ellen Heitlinger
Published: (2023-12-01)

PSMA-Directed Theragnostics: Transforming Prostate Cancer Landscape
by: Alex Friedlaender, et al.
Published: (2023-03-01)